

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/64, 15/86, A61K 48/00	A1	(11) International Publication Number: WO 00/09713 (43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: PCT/EP99/05661 (22) International Filing Date: 5 August 1999 (05.08.99) (30) Priority Data: 9817660.5 13 August 1998 (13.08.98) GB (71) Applicant (for all designated States except US): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. [IT/IT]; Via Pontina Km. 30.600, I-00040 Pomezia (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): SAVINO, Rocco [IT/IT]; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Via Pontina KM. 30.600, I-00040 Pomezia (IT). CILIBERTO, Gennaro [IT/IT]; Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A., Via Pontina KM. 30.600, I-00040 Pomezia (IT). LA MONICA, Nicola [IT/IT]; Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A., Via Pontina KM. 30.600, I-00040 Pomezia (IT). (74) Agents: WALTON, Seán, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ADENOVIRAL VECTORS ENCODING ERYTHROPOIETIN AND THEIR USE IN GENE THERAPY		
(57) Abstract Helper dependant adenoviral vectors encoding erythropoietin (epo) provide high levels of epo to achieve a long-term therapeutically effective dosage, and allow for repeat administration to patients with disorders such as anaemia of Chronic Renal Failure (CRF), anaemias due to beta-thalassaemia, and sickle cell anaemia (SCA).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ADENOVIRAL VECTORS ENCODING ERYTHROPOIETIN
AND THEIR USE IN GENE THERAPY

The present invention relates to the delivery of erythropoietin
5 (EPO) to a mammal. More particularly, the present invention
relates to provision of EPO in a mammal by means of expression
from encoding nucleic acid included in an expression vector,
that is by means of gene therapy. The present invention is
based on the inventors' experimental demonstration that
10 therapeutic levels of EPO can be achieved using helper-
dependent adenoviral (Hd-Ad) vectors, which levels are far
beyond any levels previously attained using a variety of
vectors, including adenoviral (Ad) vectors (i.e. non-helper-
dependent).

15

Erythropoietin (EPO) is a protein of great interest because of
its therapeutic usefulness in a variety of diseases. As is
well known, the gene for human EPO was cloned by Amgen (see
e.g. WO85/02610, EP-A-0148605) and recombinantly produced EPO
20 (rEPO) has attained a huge market (in excess of 2.9 billion
dollars). Currently, rEPO is administered to patients in
protein form.

Despite its success, there is a number of problems with
25 delivery of rEPO resulting in various unmet clinical needs,
primarily because of the prohibitive cost of providing
sufficient rEPO to achieve a long-term therapeutically

effective dosage. Sufferers include individuals with anaemia of Chronic Renal Failure (CRF), anaemias due to beta-thalassaemia, and sickle cell anaemia (SCA). Large numbers of such individuals go untreated despite the fact that good
5 therapeutic results can be achieved as long as enough EPO is provided.

In CRF there is an irreversible decline of kidney function, and the patients manifest a sequel of renal dysfunctions, including
10 anaemia, but do not necessarily require dialysis except at the end stage renal disease (ESRD). At this stage the patient require either regular dialysis or kidney transplant.

CRF patients may be treated with rEPO, such treatment involving
15 starting doses of 50-100 U/Kg, three times weekly, to achieve an increment of at least 5-6 point in the haematocrit. (Note that *in vivo* bioactivity of EPO is generally determined by the simple measurement of increase in haematocrit (Hct) by centrifugation of heparinsed blood in capillary tubes.) If
20 this is not achieved within 8 weeks, the dose needs to be increased. Maintenance doses need to be individualised (Hct increase over 48%, are possibly deadly), with average of 75 U/Kg three times weekly, but ranging from 12.5 to 525 U/Kg three times weekly.

25

Circulating rEPO half life is of 4-13 hours if administered i.v., or 25-30 hours after s.c. administration. Over 95% of CRF

patients respond well to the treatment, with a measurable Hct increase, and all are reported to become transfusion-independent after 2 months of treatment.

- 5 In both beta-thalassaemia and sickle cell anaemia the formation of a normal $\alpha_2\beta_2$ haemoglobin (Hb) is impaired. Studies in baboons demonstrate that large doses (800-9,000 U/kg i.v.) of recombinant human EPO given i.v. increase gamma-globin chain synthesis and foetal Hb (AL-Khatt et al., N. En. J. Med., 1987,
10 317: 415-420).

Clinical trials with rEPO in SCA and beta-thalassaemia, with average doses of 500-1500 U/kg, show a rise in RBC count, Hb content and Hct. In SCA a significant increase of foetal Hb
15 correlates with improved quality of RBC, reduced sickling episodes and improved quality of life.

There is no report of the insurgence of anti-EPO antibodies in CRF patients, even those treated for over 4 years, nor in
20 patients with SCA or beta-thalassaemia.

What denies many individuals rEPO treatment is the costs of providing so much: $\geq 1,500$ U/kg is required three times weekly for significant Hct increase and induction of γ -globulin
25 synthesis in SCA patients.

The provision of an effective system for delivery of sufficient

EPO would have ready application given the proven therapeutic effectiveness of the protein in diseases such as those discussed above.

- 5 The dosage of biologically active circulating EPO required to reach the therapeutic window for Hb-F stimulation is believed to be in excess of 0.900 U/ml (given that >1,5000 U/Kg three times weekly is necessary, and that the half life of EPO administered s.c. is 18hrs). To date, despite many attempts
- 10 using numerous approaches, there has been no report of such a level being achieved using a gene therapy approach, i.e. delivery of EPO by means of expression in the body from encoding nucleic acid conveyed within a recombinant vector.
- 15 Delivery of EPO cDNA by different means are described in the prior art. The highest level of circulating EPO reported is around 0.75 U/ml (Kessler P.D. et al. 1996, PNAS 93, 14082-7), well below the level required to have beneficial effect in SCA or beta-thalassaemia.

20

Studies have been published by other laboratories using Adeno-vectors carrying the EPO gene which have shown limitations of these vectors in providing appropriate gene dosage and controlled hormonal release over a prolonged period of time.

25

Descamp et al., (1994, Human Gene Therapy 5:979-985) used an adenovector containing monkey EPO cDNA under the control of an

RSV-LTR promoter. A minimum of 5×10^9 viral PFUs (plaque forming units) were required to give Hct increase (observed in a subset of animals). Example 15 below includes a comparison of results achieved using an embodiment of the present

5 invention with results of Descamp et al.

Svensson et al. (1997, Human Gene Therapy 8:1797-1806) used an adenovector containing a mouse EPO coding sequence operably linked to an EF1 α promoter, injecting particles i.m. Maximal
10 EPO levels with 10^9 PFUs/mouse was 90 mU/m. No real dose response was shown. The same group earlier published Tripathy et al., 1996 Nat Med., 2: 545-50, and Tripathy et al., 1996 PNAS USA 93, 10876-80, in the latter of which naked DNA was injected into muscle, the maximal EPO levels achieved in blood
15 being 50 mU/ml. The minimal amount of naked DNA needed to observed Hct increase was 10mg/mouse, 500 mg/kg, corresponding to 35 mg/injection for a human of average 70 kg weight, a huge amount. Example 14 below includes comparison of results achieved using an embodiment of the present invention compared
20 with the results of Svensson et al.

Remarkably, the experimental work described below demonstrates that use of embodiments of the present invention allows for circulating EPO levels of 300 U/ml to be achieved, i.e. far in
25 excess of the level required for effective therapy.

Furthermore, these levels can be obtained following a single injection and sustained over long periods of time.

The present invention in various aspects and embodiments employs an EPO encoding sequence within an adenovirus vector in which the entire Adenoviral genome coding sequences have been removed and substituted with exogenous DNA stuffer sequences,
5 generally a Helper-Dependent Adenovirus vector (Hd-Ad).

A general aspect of the present invention provides for the use of such an adenoviral vector in delivery of erythropoietin to an individual. Such delivery is especially at a level in the
10 serum of the individual of at least about 0.005, or 0.1, or 0.5, or 1, or 2, or 3, or 4, or 5, or 6, or 7, or 8, or 9, or 10 U/ml, and may be greater than about 10 U/ml, such as about 20, 30, 40 or 50 U/ml. As noted, levels of up to 300 U/ml are achievable using embodiments of the present invention.

15 One unit (U) of EPO corresponds approximately to 10 ng of pure protein and can be defined with reference to the international standard WHO-EPO 2nd International Reference Preparation (Annable et al., 1972, Bull. Wld, Hlth. Org. 47: 99) as the
20 amount that is required to produce equivalent [³H]-thymidine incorporation into spleen cells from phenylhydrazine-treated mice to that expressed by 1 unit of the WHO standard preparation, or the amount needed to induce 50% of maximum growth (FC50) in erythroleukaemia cells, TFl.

25

One advantage that may be attained using the present invention is a dose response curve, making it possible to calculate the

amount of vector to administer to achieve a desired level of circulating EPO.

One aspect of the present invention provides a method of
5 delivering erythropoietin (EPO) to an individual, the method including provision in the individual of an adenoviral vector as disclosed including nucleic acid encoding erythropoietin operably linked to regulatory sequences for production of erythropoietin in the individual by expression from the nucleic
10 acid, especially whereby on such expression a dosage of erythropoietin at a level as indicated.

A further aspect of the present invention provides an adenoviral vector as disclosed including nucleic acid encoding
15 erythropoietin operably linked to regulatory sequences for production of erythropoietin by expression from the nucleic acid. Such a vector may be provided for use in delivery of erythropoietin to an individual, especially for delivery of erythropoietin at a level in the serum of the individual as
20 indicated.

A still further aspect of the present invention provides the use of an adenoviral vector as disclosed including nucleic acid encoding erythropoietin operably linked to regulatory sequences
25 for production of erythropoietin by expression from the nucleic acid, in the manufacture of a medicament for delivery of erythropoietin to an individual, especially to the serum at a

level as indicated.

A feature of embodiments of the present invention is the opportunity for repeat administration. Adenoviral vectors
5 according to the invention may be re-administered to an individual to which such a vector (e.g. even of the same serotype) has previously been administered, e.g. at or more than about one month, e.g. 35 days, preferably at or more than about two months, more preferably at or more than about three
10 months, more preferably at or more than about four months, more preferably at or more than about six months, more preferably at or more than about nine months, more preferably at or more than about 12 months, more preferably at or more than about 18 months, more preferably at or more than about 24 months from
15 the first, or previous, administration. The re-administration may result in equivalent or greater levels of erythropoietin in the serum and/or increase in haematocrit.

The present invention allows for delivery of erythropoietin to
20 achieve stable elevated levels in the serum.

For each aspect, either in addition to provision in the serum at at least the indicated level or alternatively, the provision may be for delivery of erythropoietin for an increase in the
25 haematocrit reading of about 5%, or about 10%, or about 15%, or about 20%. The level of haematocrit may reach about 30%, or about 35%, or about 40%, or about 45%, or about 50%. For

instance an increase of 10-15% on a reading of 30% for an anaemic level, i.e. to physiological levels of around 40-45%, may be achieved.

- 5 The level of erythropoietin and/or increase in haematocrit may be maintained to at least about 70%, more preferably at least about 80%, more preferably at least about 90%, more preferably at least about 95% of the level attained (that is attained following the first or previous administration) for at least
- 10 about one month, preferably at least about two months, e.g. at least 84 days, more preferably at least about three months, more preferably at least about four months, e.g. at least 140 days, more preferably at least about six months, more preferably at least about nine months, more preferably at least
- 15 about 12 months, more preferably at least about 18 months, more preferably at least about 24 months from the first, or previous, administration.

- The individual may have a disease or disorder such that
- 20 delivery of erythropoietin is of benefit or has a therapeutically beneficial effect. Delivery of erythropoietin may ameliorate one or more symptoms of the disease or disorder.

- Diseases and disorders that may be treated in accordance with
- 25 the present invention include anaemia of Chronic Renal Failure (CRF), anaemias due to beta-thalassaemia, and sickle cell anaemia (SCA), other anaemias including following radiation

therapy or chemotherapy.

As indicated by the experiments included below, such high levels of expression may be achieved using embodiments of the present invention (e.g. using the EFl α promoter) that an excess of EPO may be delivered, which may result in side-effects in certain situations or individuals.

In SCA and in beta-thalassaemia it appears that excess production of EPO would not be detrimental, because even at very high EPO level, the maximum production of foetal-Hb is naturally limited and will not result in a dangerous increase of the Hct.

For delivery in other situations, e.g. for treatment of CRF patients, some more stringent regulation of gene expression may be employed, e.g. using a different promoter.

Parks et al. (1996). Proc. Natl. Acad. Sci. USA 93:13656-13570 describes a convenient packaging system for the large scale preparation of Helper-Dependent adenovirus vectors. In this system the Helper-Dependent vector is transfected in 293Cre cells, stably expressing the Cre recombinase. The cells are infected with the Helper Adenovirus, which furnishes in *trans* all the functions needed for the vector replication and packaging. The packaging signal of the Helper Adenovirus is flanked by two lox P sites; which are recognized by the Cre

recombinase expressed in 293Cre cells: the packaging signal is thus removed and the majority of the Helper Adenovirus genomes cannot be packed, leading to preferential packaging of the Vector. After full cytopathic effect is obtained, the crude
5 lysate is used to infect fresh 293Cre cells, coinfecting with Helper Adenovirus: repeated cycles of infection bring to amplification of the vector. Roughly 20% of the Helper Adenovirus genomes escape Cre-mediated packaging signal excision, leading to the generation of a small amount of Helper
10 Adenovirus. This small amount of contaminant can be easily removed by CsCl buoyant density centrifugation, leading to packaged helper-dependent vector preparations which are highly purified, with less than 0.1% helper Adenovirus contamination (Parks et al., 1996).

15

Suitable vectors may include the pSTK120 backbone employed by Morsy et al. (July 1998) *PNAS USA* 95: 7866-7871 in a HD-Ad vector for delivery of a leptin transgene to *ob/ob* mice.

20 The erythropoietin encoding sequence may be placed within the vector in any site that operably links it to the regulatory sequences for expression whereby the indicated level of erythropoietin and/or increase in haematocrit is achieved on expression in an individual. Suitable cloning sites are *SWA I*
25 (NT 8096), *EAG I* (NT 16520), *FSE I* (NT 25653), *SRf I* (NT 14735), *EcoRI* (NT 24916, *BspEI* (NT 24321).

The regulatory sequences for expression will include a promoter.

By "promoter" is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA).

"Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.

Other regulatory sequences including terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences may be included as appropriate, in accordance with the knowledge and practice of the ordinary person skilled in the art: see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1992.

As noted, different promoters and other regulatory sequences may drive production of erythropoietin with different levels of promoter activity.

5 "Promoter activity" is used to refer to ability to initiate transcription. The level of promoter activity is quantifiable for instance by assessment of the amount of mRNA produced by transcription from the promoter or by assessment of the amount of protein product produced by translation of mRNA produced by
10 transcription from the promoter, for instance by determining protein activity or evidence of protein activity (such as for erythropoietin an increase in haematocrit in an individual). The amount of a specific mRNA present in an expression system may be determined for example using specific oligonucleotides
15 which are able to hybridise with the mRNA and which are labelled or may be used in a specific amplification reaction such as the polymerase chain reaction. Use of a reporter gene facilitates determination of promoter activity by reference to protein production.

20

EPO units (U/ml) may be assayed using the Quantikine IVD rhEpo ELISA kit of Accurate Chemical & Scientific, Minneapolis, MN, USA, which is calibrated by the manufacturer against the international standard WHO-EPO 2nd International Reference
25 Preparation (Annable et al., 1972, Bull. Wld, Hlth. Org. 47: 99).

Suitable promoters for use in aspects and embodiments of the present invention include the human elongation factor 1 α (EF1 α) promoter, viral promoters such as CMV or RSV promoters, promoters linked to tet operator sequences, promoters linked to
5 GAL4 binding sites, hypoxia inducible promoters, such as the Hypoxia Responsive Elements (HRE) naturally found in the erythropoietin gene.

Adenoviral particles containing nucleic acid encoding
10 erythropoietin produced in accordance with the present invention may be formulated in pharmaceutical compositions. These compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be
15 non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

20 Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as
25 ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Following production of adenoviral particles according to the invention and optional formulation of such particles into compositions, the particles may be administered to an individual, particularly human or other primate.

Administration may be to another mammal, e.g. rodent such as mouse, rat or hamster, guinea pig, rabbit, sheep, goat, pig, horse, cow, donkey, dog or cat.

This may be for a therapeutic purpose, e.g. in delivery of a functional gene encoding an authentic biologically active product in a method of gene therapy, to treat a patient who is unable to synthesize that product or unable to synthesize it at the normal level or in normal form, thereby providing the effect provided by the wild-type and ameliorating one or more symptoms of the relevant disease.

Administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual
5 amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, or in a veterinary
10 context a veterinarian, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in
15 Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

The number of Adenovector particles to be administered in accordance with the present invention may be from around 1×10^3 /g to about 1×10^6 /g body weight, and may be about 1×10^3 ,
20 or about 1×10^5 , or about 1×10^6 , preferably about 1×10^4 /g body weight. Embodiments of the present invention allow for delivery of lower numbers of particles to be administered compared with work described in the prior art noted above, e.g.
25 less than 1×10^9 , more preferably less than 1×10^8 .

A composition may be administered alone or in combination with

other treatments, either simultaneously or sequentially dependent upon the condition to be treated. For example, in the case of SCA treatment may be in combination with hydroxyurea.

5

Delivery to a non-human mammal need not be for a therapeutic purpose, but may be for use in an experimental context. The erythropoietin for administration to a mammal of interest is preferably the erythropoietin of that species (including

10 modified forms thereof) or a related species. Thus, for example, human EPO will generally be used for administration to humans (much as in the experiments described below murine EPO was administered to mice).

15 Further aspects and embodiments of the present invention will be apparent to those of ordinary skill in the art, in view of the above disclosure and following experimental exemplification, included by way of illustration and not limitation, and with reference to the attached figures.

20

Brief Description of the Figures

Figure 1 shows structures of HD(pSTK-ITR-mEPO)Ad and HVAd-mEPO viruses.

Figure 1A illustrates HD(pSTK-ITR-mEPO)Ad, which is based
25 on an STK-120 backbone (Morsy et al., 1998) containing, in the following order: the Ad5 inverted terminal repeat (L-ITR) and the packaging signal (Ψ), 440 bp (nucleotides 1-440); a 16.054-

bp fragment of hypoxanthine guanine phosphorybosyltransferase (HPRT stuffer, nucleotides 1.799-17.853 in gb:humhprt_b); a *HindIII* 9,063-bp fragment of C346 cosmid (nucleotides 12.421-21.484 in gb:humhprt_b); the right-end terminus of Ad5, composed of the ITR sequence, 117 bp (R-ITR: nucleotides 35.818-35.935). Total length of the STK-120 backbone is 25.674 bp. The 2.561-bp mEPO expression cassette is cloned in the unique *SwaI* site in the HPRT stuffer, bringing the size of HD-mEPO to 28.235-bp. ITR: Adeno-Associated Virus (AAV) Inverted Terminal Repeat; GHpA: bovine Growth Hormone gene polyadenylation signal. The intron contained in the EF1a promoter region is indicated by a thinner line.

Figure 1B illustrates HVAd-mEPO, which is based on the backbone of pHVAd1, 35.321 bp. Homologous recombination inserted the 2.202-bp mEPO expression cassette (without the AAV ITRs), causing at the same time a 3.181-bp deletion (nucleotides 342-3.523) of E1 sequences. Total length of HVAd-mEPO is therefore 34.342 bp.

Figure 2 shows a comparison of EPO levels produced in HeLa cells following infection with Hd-AV according to the invention or an adenovector encoding EPO (HV Ad-mEPO) generated according to Chartier et al. (1996). *J. Virol.* 70:4805-4810, indicating twice as many of the latter required to produce an equivalent level of EPO as with the relevant embodiment of the invention, the experiments being described in Example 4.

Figure 3 shows *in vivo* comparison between hd(pSTK-ITR-mEPO)Ad and HVAd-mEPO. The viruses hd(pSTK-ITR-mEPO)Ad and HVAd-mEPO were infused side-by-side in the tail vein of healthy adult female BALB/c mice.

5 Figure 3A shows results of experiments in which HVAd-mEPO was injected in the dose range from 3×10^6 to 3×10^7 pfu (n=5 each).

Figure 3B shows results of experiments in which hd(pSTK-ITR-mEPO)Ad was injected at the same doses and two other mice
10 groups, injected with doses of 3×10^5 and 1×10^6 i.u. (n=5 each), were also included in the experiment.

Figure 4 shows mouse EPO and haematocrit levels in BALB/c mice. Groups of healthy adult female BALB/c mice (n=5) were infused
15 in the tail vein with various doses of hd(pSTK-ITR-mEPO)Ad virus (from 3×10^5 to 8×10^8 transducing units).

Figure 4A shows mEPO levels (in mIU/ml). For mice injected with the 3×10^5 i.u. of virus and with PBS, the mEPO levels were below the 5 mIU/ml lower detection limit of the assay and
20 are not shown in the figure.

Figure 4B shows haematocrit levels. The groups of mice injected with 8×10^8 and 1×10^9 i.u. had haematocrit levels similar to mice injected with 7×10^7 or 3×10^7 i.u. and are not shown for clarity of illustration.

25

Figure 5 shows mouse EPO and haematocrit levels in DBA/2J and CD-1 mice. Groups of healthy adult female DBA/2J mice (n=6)

were infused in the tail vein with various doses of hd(pSTK-ITR-mEPO)Ad virus (from 3×10^5 to 1×10^7 transducing units).

Figure 5A shows mEPO levels.

Figure 5B shows haematocrit levels.

5 Figure 5C shows results of experiments in which groups of healthy adult female CD-1 mice (n=9) were infused in the tail vein with the same doses of hd(pSTK-ITR-mEPO)Ad virus: haematocrit levels are shown.

10 Figure 6 shows haematocrit measurements in Balb/c mice at various days following first and second injections of Hd-AV according to the invention, as described in Example 10.

Figure 7 shows results of experiments involving virus
15 readministration a long time after the first injection.

Figure 7A shows results of experiments in which the same mice used in the experiments of which results are shown in Figure 4, which received 3×10^5 i.u. of hd(pSTK-ITR-mEPO)Ad at time 0, were reinjected with a second dose of 3×10^5 i.u.
20 (indicated by the arrow) 235 days after the first injection. Haematocrit levels are shown.

Figure 7B shows results of experiments in which a subset of the mice used in the experiments of which results are shown in Figure 5, which received 3×10^5 i.u. of hd(pSTK-ITR-mEPO)Ad
25 at time 0, were reinjected with a second dose of 3×10^5 i.u. (indicated by the arrow) 215 days after the first injection. Haematocrit levels are shown.

Figure 8 shows results of blood measurement after subtotal nephrectomy in rats.

Figure 8A shows Blood Urea Nitrogen (BUN) levels.

Figure 8B shows haematocrit levels.

5 Empty triangles: control rats. Empty circles: subtotally nephrectomized rats, injected i.v. with PBS 47 days after the surgery. Filled squares: subtotally nephrectomized rats, injected i.v. with hd(pSTK-ITR-mEPO)Ad (3×10^6 i.u.) 47 days after the surgery. Arrows indicate virus or PBS injections.

10

Figure 9 shows haematocrit measurements in CD-1 mice at various days following injection of Hd-AV according to the invention or the adenovector encoding EPO (AdmEPO) of Svensson et al. (1997), indicating a much higher pfu (1000-fold greater)
15 required for the adenovector to achieve a haematocrit increase comparable with that achieved using the present invention, the relevant experiments being described in Example 14.

Figure 10 shows haematocrit measurements in DBA/2J mice at
20 various days following injection of Hd-AV according to the invention or the adenovector encoding EPO (Ad.RSVEpo) of Descamp et al. (1994), indicating a potency for the relevant embodiment of the present invention of roughly 10,000-fold greater, as described in Example 15.

25

EXPERIMENTAL INTRODUCTION AND DISCUSSION

Vectors expressing Mouse EPO(a) mEPO expression cassette

5 The mEPO cDNA (Shoemaker and Mitsock (1986). Mol. Cell. Biol.
6:849-858) was cloned by PCR with an overlapping set of
synthetic oligonucleotides. An EPO expression cassette was
constructed under the control of the EFl α promoter (Kim et al.,
1990, Gene 91: 217-223).

10

(b) pSTK-ITR-mEPO

EPO expression cassettes were inserted between AAV-ITRs (which
would allow for site-specific integration of the EPO encoding
15 sequence if used in conjunction with Adeno-Associated Virus
(AAV) Rep integrase), and this was cloned in a HD adeno vector,
pSTK120 backbone, obtained from Dr. S. Kochaneck, formerly at
Baylor College, now University of Koln) (Schnieder et al., Feb.
1998, Natural Genetics 18: 180-183; Morsy et al. (July 1998)
20 PNAS USA 95: 7866-7871).

Results

The vector pSTK-ITR-mEPO was amplified in 293-cre cells and
25 purified. The genomic structure of the packaged virus was
characterised and was found to be homogeneous and not to have
undergone any detectable rearrangement. Infection of cultured

cells with this vector gave rise to elevated production of mEPO *in vitro*.

In vivo delivery of pSTK-ITR-mEPO was studied in BALB/c, in CD-
5 1 and DBA/2J mice. Viral preparations were injected at
different doses ranging from 0.1 μ l to 250 μ l (1 μ l contains
approximately 2×10^9 physical particles corresponding to
approximately 2×10^7 transducing units). Both circulating EPO
levels and haematocrit (HCT) increases were monitored.

10

Discussion

From the data collected, some conclusions can be drawn:

- (1) EPO levels in the blood are stable for more than five
15 months and a precise dose-response curve can be observed;
- (2) Although at doses above 1 μ l a saturating increase of HCT
are obtained, doses of 1 μ l and below lead to submaximal but
stable HCT increases well within physiological ranges;
- (3) The efficacy *in vivo* on a particle basis of the HD-Ad mEPO
20 vector is far superior (1,000- to 10,000-fold) with respect to
first generation Adenoviruses carrying mouse EPO reported in
the literature.

In particular, the last result is surprising and totally
25 unexpected.

The extraordinary higher *in vivo* transduction efficiency of the

HD-Ad mEPO, with respect to first generation Adenoviruses carrying mouse EPO reported in the literature, has the following advantages:

- (a) low doses of virus are sufficient to achieve statistically significant biological effect;
- (b) there is total absence of detectable immune response, which correlates with long lasting effect;
- (c) it is possible to re-inject the virus and obtain again biological effect, consistent with the absence of any detectable neutralising antibodies after first injection.

EXAMPLE 1

Construction of hd(pSTK-ITR-mEPO)Ad: a helper dependent Ad/AAV recombinant vector carrying the Mouse EPO gene

(a) mEPO expression cassette

The cDNA coding for mouse EPO (mEPO) was assembled from synthetic oligonucleotides (Stemmer et al. (1995). Gene 164:49-53). Roughly 30 bp of the 5' untranslated region (UTR) upstream of the initiator ATG were also synthesised, because it has been shown that a construct containing such a region of the 5' UTR is able to direct synthesis of mEPO in COS cells (Shoemaker and Mitsock (1986). Mol. Cell. Biol. 6:849-858.). For cloning purposes, a *Pst*I restriction site was added at the 5' end of the cDNA and a *Bam*HI restriction site was added at the 3' end of the cDNA, both sites added by PCR technique.

The cDNA was cloned *Pst*I-*Bam*HI in pBluescript II and was verified by sequencing. *In vitro* transcription and translation was used to provide confirmation the vector encoded a protein of the expected size.

5

The bovine growth hormone poly A site was amplified by PCR from plasmid pCDNA3 (Invitrogen, nucleotides 983-1249) at the same time adding a *Not*I site at the 3' end for cloning purposes. The bovine growth hormone poly A site was cloned *Xba*I-*Not*I in

10 pBluescript II, downstream of the mEPO cDNA.

A 1.2 kb DNA fragment, containing the enhancer/promoter of the human elongation factor 1 α gene, was excised (with *Hind*III and *Eco*RI) from the expression cassette present in pEF-BOS

15 (Mizushima and Nagata (1990). Nucl. Acids Res. 18:5322) and it was cloned *Hind*III-*Eco*RI in pBluescript II, upstream of the mEPO cDNA. The chosen regulatory element (which contains also an intron) is known to give *in vivo* expression levels higher than viral promoters like RSV-LTR of CMV and to be stable over
20 time in immunocompetent animals (Guo et al. (1996). Gene Therapy 3:820-810).25 The entire expression cassette is flanked by unique restriction sites (*Kpn*I, *Sal*I, *Cla*I and *Hind*III at the 5'; *Not*I, *Bss*HII, *Pvu*II and *Pvu*I at the 3') which allow easy excision from the plasmid and directional cloning in a gene therapy vector of interest. The expression cassette is compact, having a minimal

size of only 2 Kb, which can be extended up to 5 Kb by inclusion of plasmid vector sequences.

The mEPO expression cassette was transfected in human 293 cells. While the mEPO cDNA directed the synthesis of a polypeptide of apparently 21 kDa by *in vitro* transcription/translation (in good agreement with an expected size of 24 kDa for a 192 aa polypeptide), in the supernatant of the transfected 293 cells an anti-hEPO monoclonal antibody (cross-reactive with mEPO), recognized a protein migrating with an apparent molecular weight of 37 kDa, in good agreement with the 34 kDa reported molecular weight for natural mEPO, which is due to post-translational modification (mEPO has 3 potential N-linked glycosylation sites). With an ELISA kit developed for hEPO, but which also recognises mEPO, it was determined that 14 hours post-transfection the levels of mEPO in the cell culture supernatants already exceeded 200 pg/ml, and at 40 hours post-transfection the mEPO levels were much higher (judging by Western blot analysis), totally out of scale in the ELISA assay.

(b) pSTK-ITR-mEPO plasmid

The mEPO expression cassette (mEPO cDNA flanked by the enhancer/promoter of the human Elongation factor 1 α gene and by the bovine GH poly A signal) was inserted between AAV ITRs.

The ITRs are the minimal signal sequence required for rescue, replication, packaging and integration of the AAV genome (Carter, B.J. in "Handbook of Parvoviruses", ed. P. Tijsser, CRC Press, pp.155-168; WO96/36364). Targeting of integration
5 involves the AAV rep gene products. In particular, the larger polypeptides Rep 78 and Rep 68 have been shown to bind *in vitro* the AAV ITRs and the aavsl, and possess helicase and site-specific endonuclease activities which may be required for AAV replication as well as AAV integration. See for example
10 Shelling, A. N., et al. (1994). *Gene Ther.* 1, 165-169; Balagué, C., et al. (1997). *J. Virol.* 71, 3299-3306; Surosky R.T., et al (1997) *J.Virol.* 71,7951-7959.

The entire construct was subcloned in the unique *SmiI*
15 restriction site of the restriction-dependent hd adenoviral vector pSTK120, generating pSTK-ITR-mEPO. pSTK120 is a pBluescriptIIKS-based plasmid that contains (in the following order) the Ad5 inverted terminal repeat (ITR) sequence and the packaging signal ψ , 440 bp (nucleotides 1-440); a 16,054 bp
20 stuffer fragment of hypoxanthine guanine phosphoribosyltransferase (nucleotides 1,799-17,853 in gb:humhprt); a *HindIII* 9,063-bp fragment of C346 cosmid (nucleotides 12,421-21,484 in gb:L31948); and the right-end terminus of Ad5, composed of the ITR sequence, 117 bp
25 (nucleotides 35,818-35,935).

EXAMPLE 2

Production of hd(pSTK-ITR-mEPO)Ad: a hd adenovirus expressing mEPO

In order to follow the amplification of the hd mEPO Ad virus,
5 an infection assay was set up.

HeLa cells (which have no endogenous EPO background production) were seeded in 24-well plates and infected with cell lysates derived from 293cre cells amplifying the hd mEPO Ad virus.

10 After two washes to remove the EPO produced by the 293cre cell, HeLa cells were cultured for 24 hours and EPO was detected in the supernatant with an ELISA kit.

EPO production was detected from HeLa cells infected with the
15 passage 1 (P1) derived from 293cre transfected with pSTK-ITR-mEPO (after linearization with *PmeI* restriction which, by cleaving at the two *PmeI* flanking sites releases the linear pseudo-viral pro-genome and eliminates the pBluescriptII plasmid backbone) and infected with the helper virus AdLC8cluc.

20

EXAMPLE 3

Amplification and characterization of hd(pSTK-ITR-mEPO)Ad

Two independent amplifications of the hd(pSTK-ITR-mEPO)Ad
25 helper-dependent Adenovirus in 293cre4 cells were carried out. Aliquots of lysates from the various amplification passages were tested for induction of EPO production in the HeLa

infection assay as described in Example 2, with the following results:

Passage	Amplification A		Amplification B	
	EPO, mU/ml	Increase	EPO, mU/ml	Increase
P1	1.0	1	3.6	1
P2	10.4	10	55.9	15
P3	40.0	40	178.2	50
P4	23.9	24	84.5	23
P5	37.3	37	120.5	33
P6	448.7	449	1695.0	470
P7	4920.0	4920	11500.0	3194
P8	44300.0	44300	43900.0	12195

The virus increase at any given passage can be easily obtained simply dividing the EPO levels at that passage by the EPO levels at passage 1.

Although there was lack of amplification at passages 4 and 5 in both experiments, at passage 8 there was an increase of at least 4 logs in the amount of virus-induced EPO production by infected HeLa cells.

The helper-dependent virus was prepared on large scale, and viral DNA was extracted from part of the preparation, and was restricted with 6 different enzymes, side by side with the original pSTK-ITR-mEPO plasmid. No rearrangement was detectable in the restriction pattern.

Aliquots of the hd(pSTK-ITR-mEPO)Ad adenovirus CsCl purified preparation (up to 10 μ l in duplicate) were used in a plaque forming assay on 293 cells to measure helper virus

contamination. Helper virus titre was measured as 3×10^6 pfu/ml.

The concentration of physical particles in the preparation was measured as 2×10^{11} /ml, therefore the titre of EPO transducing units might be close to 10^9 /ml. The titre of EPO transducing units was determined as described in Example 4.

EXAMPLE 4

10 *Construction of HVAd-mEPO: a Δ E1 Ad vector carrying the Mouse EPO gene and its use to determine the infectious titer of hd(pSTK-ITR-mEPO)Ad*

A Δ E1 Ad vector containing the same mEPO expression cassette as in the illustrative embodiment of the present invention was generated according to Chartier et al., 1996, (HVAd-mEPO) and its titre was measured as 1.3×10^9 pfu/ml by conventional plaque assay.

20 Different volumes of hd(pSTK-ITR-mEPO)Ad and of HVAd-mEPO virus preparations were used in the HeLa infection assay described in Example 2 and the concentration of EPO in the supernatants of the infected cells determined. The results are shown in Figure 2.

25

The concentration of infectious units of the hd(pSTK-ITR-mEPO)Ad preparation is roughly 2-fold higher as compared to the

concentration of infectious units of the HVAd-mEPO preparation.
The titre of the HVAd-mEPO preparation was measured as 1.3×10^9
pfu/ml (by conventional plaque assay) so the titre of the
hd(pSTK-ITR-mEPO)Ad preparation can be estimated as 2.6×10^9
5 pfu-Equivalent/ml (pfu-E/ml).

Considering that the concentration of physical particles titre
of the hd(pSTK-ITR-mEPO)Ad preparation was measured as $2 \times$
 10^{11} /ml (see previous example), the ratio pfu:physical particles
10 can be estimated as roughly 1:100, in perfect agreement with
what is known for $\Delta E1$ Ad vectors (Barr and Kay (1997). Methods
for delivery of Genes to hepatocytes *in vivo* using recombinant
Adenovirus vectors. In Gene Therapy Protocols. P. D. Robbins
editor. Human Press, Totowa, New Jersey. 205-212).

15

Finally, considering that helper virus titre in the hd(pSTK-
ITR-mEPO)Ad preparation was measured as 3×10^6 pfu/ml (see
previous example), the percentage of helper virus contamination
20 can be estimated as roughly 0.1%, therefore 99.9% of
infectious units in the hd(pSTK-ITR-mEPO)Ad preparation are
helper-dependent viral particles.

In the following examples, the doses used *in vivo* are reported
25 as pfu-E and not as volumes or physical particles.

EXAMPLE 5

In vivo testing of hd(pSTK-ITR-mEPO)Ad in BALB/c mice

To test efficiency of gene delivery *in vivo*, the following doses of hd(pSTK-ITR-mEPO)Ad were injected in the tail vein of 8-week old immunocompetent female BALB/c mice: 8×10^8 pfu-E, 1×10^8 pfu-E, 7×10^7 pfu-E, 3×10^7 pfu-E, 1×10^7 pfu-E, 3×10^6 pfu-E (groups of 5 mice for each dose). Control mice were injected in the tail vein with saline solution (PBS).

Serum mEPO levels and haematocrit were measured at various times after virus injection. The results are summarised in Figure 4.

Figure 4 shows that there is an evident dose-response in the levels of serum EPO as a function of the viral dose injected, and EPO levels seem to be stable until day 105 after injection (this being the last time point at which mEPO detection was performed). Early deaths occurred in the high dose injected groups: all animals injected with 8×10^8 pfu-E died within 42 days after virus injection, all animals injected with 1×10^8 pfu-E died within 63 days after virus injection, all animals injected with 7×10^7 pfu-E died within 105 days after virus injection and 3 out of 5 animals injected with 8×10^8 pfu-E died within 140 days after virus injection. Autoptic analysis established that the causes of death were due to pronounced polycitemia.

Three observations on haematocrit levels can be made from Figure 4:

- (i) no dose-response could be observed at the higher doses tested (8×10^8 pfu-E and 1×10^8 pfu-E, not shown; 7×10^7 pfu-E and 3×10^7 pfu-E, Figure 4). The lack of a dose dependence of the haematocrit levels may be due, at least in part, to the high level of EPO being produced which are already at a plateau above the levels giving a dose-response in the haematocrit.
- (ii) A dose-response could be observed at the lower doses (1×10^7 pfu-E, 3×10^6 pfu-E), although haematocrit still reached high values (more than 75%) even at the 3×10^6 pfu-E dose.
- (iii) The haematocrit remains stable for at least 140 days after helper-dependent virus injection (duration of the experiment at the moment of writing).

To determine the minimal virus dose capable of giving an increase in haematocrit, a second group of BALB/c mice was injected with 1×10^6 pfu-E and 3×10^5 pfu-E virus doses. As vector dosage is decrease, a better dose-response in the rise of haematocrit levels is anticipated. The results are also summarised in Figure 4.

Figure 4 shows that mEPO is detectable in mice injected with the 1×10^6 pfu-E dose and it is stable for at least 85 days

after helper-dependent virus injection (duration of the experiment at the moment of writing); mEPO is not detectable in mice injected with the 3×10^5 pfu-E dose (detection limit of the kit 5 mU/ml of mEPO), however Figure 4 shows that these
5 mice still show an increase in the haematocrit after virus injection, when compared to PBS-injected mice. It is of note that as little as 3×10^5 pfu-E (1×10^8 physical particles) of virus (produced from as few as 10^4 293cre infected cells) are able to induce a statistically significant increase in
10 haematocrit in the strongly immunocompetent BALB/c mice, increase which is stable for at least at day 84 after virus injection.

EXAMPLE 6

15 *In vivo testing of hd(pSTK-ITR-mEPO)Ad in DBA/2J mice*

To test efficiency of gene delivery *in vivo*, the following doses of hd(pSTK-ITR-mEPO)Ad were injected in the tail vein of 8-week old immunocompetent female DBA/2J mice: 1×10^7 pfu-E, 3
20 $\times 10^6$ pfu-E, 1×10^6 pfu-E, 3×10^5 pfu-E (groups of 5 mice for each dose). Control mice were injected in the tail vein with saline solution (PBS).

Serum mEPO levels and haematocrit were measured at various
25 times after virus injection. The results are summarised in Figure 5.

Also in this immunocompetent strain a dose response to virus injection was observed for both circulating EPO levels and haematocrit increase. It is worth noting that in this strain the vector expression and efficacy is apparently much higher than in BALB/c: the 3×10^5 pfu-E dose (lowest dose tested) gives quite detectable mEPO levels, between 20 and 30 mU/ml (mEPO was undetectable in age-matched BALB/c mice injected with the same dose of virus) and the haematocrit reached levels of 83.3% 42 days after injection. Indeed, all animals injected with the three higher doses already died due to complications related to pronounced polycitemia (some animals reached 91% hct just before death); only some animals injected with the 3×10^5 pfu-E dose are surviving (4 out of 6) and their haematocrit has been stable around 83% over the last 43 days.

15

Also in this mouse strain transgene expression by the helper-dependent adenoviral vector was stable for the entire duration of the experiment (84 days at the moment of writing).

20 *EXAMPLE 7*

In vivo testing of hd(pSTK-ITR-mEPO)Ad in CD-1 mice

To test efficiency of gene delivery *in vivo*, hd(pSTK-ITR-mEPO)Ad was injected in the tail vein of 8-week old immunocompetent CD-1 female mice at the following doses: 1×10^7 pfu-E, 3×10^6 pfu-E, 1×10^6 pfu-E, 3×10^5 pfu-E (groups of 6 mice for each dose). Control mice were injected in the tail

25

vein with saline solution (PBS).

Haematocrit was measured at various times after virus injection. The results are summarised in Figure 5.

5

Again, also in this immunocompetent strain a dose response to virus injection was observed for haematocrit increase. It is worth nothing that in this strain the vector expression and efficacy is apparently higher than in BALB/c, but lower than in DBA/2J: the 3×10^5 pfu-E dose (lowest dose tested) gives haematocrit levels around 60%, therefore higher than the ones observed in age-matched BALB/c mice injected with the same dose of virus (53%), but lower than the ones observed in age-matched BALB/c mice injected with the same dose of virus (83%).

15

Therefore, as little as 3×10^5 pfu-E of virus (produced from as few as 10^4 293cre infected cells) are able to induce a very significant increase in haematocrit in all 3 immunocompetent mice strain tested, albeit with different efficacy (DBA/2J > CD-1 > BALB/c).

20

EXAMPLE 8

Follow-up of mice injected with HD(pSTK-ITR-mEPO)Ad

25 Mice injected with virus hd(pSTK-ITR-mEPO)Ad (Examples 5, 6 and 7) were followed to assess the longevity of expression.

The results for BALB/c mice (Examples 5) are shown in Figure 4. All animals injected with doses equal to or higher than 3×10^7 pfu-E died due to complications related to the pronounced polycythemia. It is remarkable to notice that the haematocrit
5 remained elevated for at least 225 days after HD(pSTK-ITR-mEPO)Ad injection at doses equal to or higher than 1×10^6 pfu-E.

The results for DBA/2J mice (Example 6) are shown in Figure 5A
10 and 5B. Again, in the group injected with 3×10^5 pfu-E of HD(pSTK-ITR-mEPO)Ad, elevated mEPO levels (Figure 5A) and, consequently, elevated haematocrit levels (Figure 5B) persisted for at least 225 days after the injection.

15 The results for CD-1 mice (Example 7) are shown in Figure 5C. In this mice also the haematocrit remained elevated in all groups for at least 220 days after the HD(pSTK-ITR-mEPO)Ad virus injection.

20 EXAMPLE 9

Induction of neutralizing antibodies against injected viruses

Humoral immune responses, in particular the induction of neutralizing antibodies against capsid proteins (Tripathy et
25 al, (1996) Nature Med 2, 545-550), are a fundamental problem in animals injected with E1-deleted adenoviruses (Mastrangeli et al. (1996) Hum Gene Ther 7, 79-87) because they can limit

further re-administration of the same or of a different adeno vector.

Formation of neutralising antibodies against hd(pSTK-ITR-
5 mEPO)Ad and HVAd-mEPO was studied in BALB/c mice. Neutralising
antibody assays were performed as described by Jooss et al.
Gene Ther 5:309, 1998, with minor modifications. Briefly, after
1h preincubation of 2×10^4 i.u. of HD(pSTK-ITR-mEPO)Ad with
serial dilutions of heat-inactivated serum [from HD(pSTK-ITR-
10 mEPO)Ad or HVAd-mEPO injected mice] in DMEM (Gibco) plus 0.2%
foetal bovine serum (50 μ l, starting 1:10), the virus was
applied onto 10^5 HeLa cells in 96-well plates. Following 1h
infection, the inoculum was sucked and 250 μ l of fresh DMEM
(Gibco) plus 10% foetal bovine serum (Gibco) were added. After
15 24h medium was harvested and mEPO concentration was measured
using the Quantikine IVD rhEPO ELISA kit (R&D System,
Minneapolis, MN) following the instruction furnished by the
manufacturer. The neutralizing antibody titer was defined as
the dilution of serum which lead to a 50% reduction of mEPO
20 levels in the cell culture supernatants compared to HeLa cells
infected with virus incubated with serum from naive mice.

Injection of 1.2×10^8 physical particles (p.p.) of the two
viruses did not significantly induce the formation of
25 neutralizing antibodies whereas, again in both cases, higher
virus doses induced neutralizing antibodies (see table below).
It is important to notice that neutralizing antibody titers

were not significantly induced upon injection of both the first generation and the HD vectors at doses low (1.2×10^8 p.p., corresponding to 3×10^6 pfu and 1.2×10^6 i.u., respectively), but still able to induce haematocrit elevation (Figure 3).

5

Formation of neutralising antibodies after hd and first generation virus injection

	Virus	Physical	Titre
		particles	
10	1 st generation	1.2×10^8	<10
	HVAd-mEPO	1.2×10^9	47
		1.2×10^{10}	130
	Helper Dependent	1.2×10^8	<10
15	hd(pSTK-ITR-mEPO)Ad	1.2×10^9	37
		1.2×10^{10}	180
	PBS	0	<10

Healthy adult female BALB/c mice were infused in the tail vein with various doses of HD(pSTK-ITR-mEPO)Ad or HVAd-mEPO, sera were harvested 35 days after virus injection and tested for neutralizing antibodies. Serial serum sera were incubated with 2×10^4 i.u. of HD(pSTK-ITR-mEPO)Ad for 1 hr and were then added 10^5 HeLa cells. The antibody titers are the dilutions of serum which lead to a 50% reduction of mEPO levels in the cell culture supernatants compared to HeLa cells infected with virus incubated with serum from naive mice. The lowest dilution tested was 1:10.

EXAMPLE 10

Readministration of hd(pSTK-ITR-mEPO)Ad in BALB/c mice

30

The feasibility of readministration of hd(pSTK-ITR-mEPO)Ad was tested in BALB/c mice, those which in the inventors' hands had been the most difficult to be transduced (Examples 5, 6 and 7).

5

Two groups of 8-week old female BALB/c mice were injected in the tail vein with 3×10^5 pfu-E of hd(pSTK-ITR-mEPO)Ad virus (control mice were injected in the tail vein with PBS solution) and haematocrit was measured at various time after virus administration. The results of the experiment are summarized in Figure 6.

As a result of virus administration, haematocrit increased in the first 3 weeks after injection, to stabilize at levels around 53%. At day 35, after the haematocrit had stabilized, the group of mice whose mean haematocrit is indicated in Figure 6 with a filled square was re-injected in the tail vein with 3×10^6 pfu-E of hd(pSTK-ITR-mEPO)Ad virus (injection indicated by an arrow in Figure 6).

20

Surprisingly, the haematocrit of re-injected mice started increasing again to reach values well above 70% 49 days after the second injection, whereas the haematocrit of mice which did not receive the second injection remained stable at levels around 53% for the entire duration of the experiment (84 days at the moment of writing).

25

These results show that hd(pSTK-ITR-mEPO)Ad virus can be very successfully re-administered even at short times after the first injection, when the biological effects of the first injection are still present.

5

*EXAMPLE 11**Long term re-administration of hd(pSTK-ITR-mEPO)Ad virus*

After the effects of the first hd-mEPO injection vanished (BALB/c) or were strongly reduced (in a subset of CD-1) it was possible to test efficiency of re-administration using also the same virus dose delivered with the first injection. Roughly 34 weeks p.i., BALB/c mice were infused again with 3×10^5 t.u of hd(pSTK-ITR-mEPO)Ad. Haematocrit rose to 52.5% 22 days after the second injection and then stabilised at the same levels observed after the first injection (Figure 7A). The kinetics of haematocrit increase after the first and the second injection were identical (Figure 7A). Virus-injected CD-1 mice show more individual variability as compared with the other strains, probably due to their outbred nature (Figure 5C).

Within the group of mice injected with 3×10^5 i.u. of hd(pSTK-ITR-mEPO)Ad (Figure 5C), the four mice with the lowest haematocrit were chosen. In this selected group the haematocrit reached 65% at 22 p.i. and slowly decreased to an average of 49.5% at 215 days p.i. (Figure 7B). These mice

were injected with a second dose of 3×10^5 i.u. of hd(pSTK-ITR-mEPO)Ad. Haematocrit rose abruptly to reach values of 78.5% 22 days after the second virus infusion, stabilizing at these high levels thereafter (Figure 7B).

5

Therefore, re-administration of the same HD virus dose used for the first injection brought the haematocrit to that same levels observed after the first administration in the case of BALB/c mice, and to levels even higher in the case of CD-1 mice, probably due to accumulation with the residual HD vector from the first administration (average haematocrit was still $49.5 \pm 2\%$ vs $44 \pm 2.1\%$ of the controls at the time of reinjection). The haematocrit levels reached after re-administration strongly suggest that efficiency of

10

15 reinjection is close to 100% even using a HD virus dose identical to the one used for the first injection. The fact that the HD virus allows both dose-escalation and long term readministration makes it unique among viral vectors.

20 EXAMPLE 12

In vivo testing of hd(pSTK-ITR-mEPO)Ad in Sprague-Dowley rats

The hd(pSTK-ITR-mEPO)Ad virus was injected into rats to

25 assess not the duration of gene expression (problems may arise due to the rat immune response against the heterologous mouse EPO transgene), but the efficacy of

transduction. This assessment was by measuring mEPO levels a short time after virus injection, before an eventual immune reponse against mEPO has the time to develop.

- 5 Doses of 2×10^8 , 2×10^7 and 2×10^6 pfu-E were injected in the caudal vein, and mEPO and Hct levels were monitored at various times after virus administration. The results were as follows:

		Days after virus injection					
10	Virus dose (pfu-E)	0 days		13 days		27 days	
		mEPO	Hct	mEPO	Hct	mEPO	Hct
	2×10^8	<5	42	767	69.1	324.6	75.1
			± 1.4	± 287	± 2	± 222.7	± 4
	2×10^7	<5	42.1	44.7	64.1	68.6	71.7
			± 3	± 19.1	± 3.8	± 53.8	± 1.8
15	2×10^6	<5	41	14.5	50.6	9.0	56.6
			± 1.7		± 1.7		± 4.3
	Control	<5	42.2	<5	45.5	<5	46.1
			± 1.9		± 0.8		± 0.3

Also in this animal species, a nice dose-response to virus injection was observed both for hct increase and circulating
 20 mEPO levels in the first 27 days after administration.

Interestingly, in order to obtain circulating EPO levels around 10 mU/ml (therapeutically effective dose to correct anemia of Chronic Renal Failure) it was necessary to inject
 25 only 3×10^5 pfu-E in mice (CD-1) and 2×10^6 pfu-E in rats (Sprague-Dowley), corresponding to a dose of as little as 1

$\times 10^4$ pfu-E/gram of body weight in both species.

Since the major current clinical indication for rEPO is anaemia of CRF (Paganini and Miller, (1993) Adv Intern Med 38, 223-243), hd(pSTK-ITR-mEPO)Ad virus injection was tested for treatment of anaemia of CRF, which develops in subtotally nephrectomized rats (Krumwiesh et al. (1988) Behring Inst Mitt 83, 193-201).

Subtotal nephrectomy was performed in a group of Sprague Dowley rats. Female Sprague-Dowley rats anesthetized with kethamine-xylazine were used in this study. A longitudinal incision from the sternum to the lower part of the hypogastrium was performed. The right kidney was totally removed and two out of three branches of the renal artery of the left kidney were ligated with a silk thread. As a result, 70-75% of the left kidney became ischemic, leaving the animal with 12.5-15% of its original kidney mass functional. In response to kidney surgery the rats became uremic [Blood Urea Nitrogen (BUN) and creatinine levels were quantified using Spotchen Kidney 2 strips (Menarini Diagnostics, Florence Italy) for profile of renal function, the Auto Dry Chemistry Analyzer SPOTCHEM SP-4410 was used for strip analysis].

25

Both plasma urea (Figure 8A) and creatinine levels increased in operated animals as compared to controls. Haematocrit

significantly decreased in partially nephrectomized animals, reaching levels around 35% roughly 6 1/2 week after surgery (Figure 8B).

5 A single dose of 4×10^6 pfu-E of hd(pSTK-ITR-mEPO)Ad virus was injected i.v. in in a group of partially nephrectomized rats 47 days after the subtotal nephrectomy. The weight of the animals at the time of injection was roughly 400 grams, therefore the dose administered was of 10^4 pfu-E/gram of
10 body weight. Virus injection did not correct the status of uremia, as the plasma urea level of virus injected rats were not significantly different from those of uninjected rats (Figure 8A). Interestingly, while subtotally nephrectomized uninjected rats showed deteriorating anaemia, haematocrit
15 increased after injection in subtotally nephrectomized virus-treated rats, reaching an average of 37.5% 28 days p.i. (Figure 8B).

EXAMPLE 13

20 *Construction of hd virus expressing rat EPO and use in treatment of nephrectomized rats*

Preceding Examples report successful treatment of healthy or partially nephrectomized rats with the HD(pSTK-ITR-mEPO)Ad
25 virus. However, in both cases anti-mEPO antibodies started appearing at day 42, preventing long-term effectiveness of the treatment. Rat EPO differs from mEPO at 10 amino acids,

clustered in three regions in the sequence.

DNA fragments containing the rat EPO-specific codons were amplified by PCR and joined to assemble a complete rat EPO
5 cDNA, verified by sequence analysis. The rat EPO cDNA was inserted in the same expression cassette used for mEPO cDNA (expression driven by the EFl α promoter, bovine growth hormone polyadenylation signal at the 3'), and the entire expression cassette has been cloned in pSTK-120. The virus
10 was amplified and amplification has been verified in the HeLa infection assay described in Example 2 up to passage 8. The virus was prepared on large scale and its genomic structure was verified by restriction with 2 different restriction enzymes: no rearrangement was detected.

15

Parallel infection assays were performed with the STK-ratePO virus and with a Δ E1 Ad vector (whose titer has been determined by plaque assay) in which the mEPO cDNA is under the control of the same EF-1 α promoter (Figure 1), as
20 described in Example 1. Supernatants of infected cells were analysed by western blotting using a mAb which is directed against the first 26 residues of the the protein (the first 26 residues of mouse and rat Epo are identical). Tests of EPO production performed in such a way allowed estimation of
25 the titer of STK-ratePO virus as 4×10^9 pfu-Equivalents/ml.

Correction of anaemia of CRF by hd(ratEPO)

Partial nephrectomy (total nephrectomy of one kidney, 2/3 kidney inactivation by artery ligation of the contralateral organ) was performed on Sprague Dowley rats as described above. The parameters of two animals randomly chosen as examples are shown in the following table. Also in this case, surgery induced anemia and uremia, although at a lower extent as compared with the previous experiment (compare the haematocrit and BUN data shown in the following table with Figure 8).

10

15

20

Days after nephrectomy		37	62	98	111	136
Virus Injected	Days after 1 st injection (STK-ratEPO 4x10 ⁶ pfu-E)		0	36	49	74
	Days after 2 nd injection (STK-ratEPO 4x10 ⁷ pfu-E)			0	13	38
	Hematocrit	34.5	39	42	43	50.5
Control	BUN (mg/ml)	32	30	30	33	38
	Weight	396	540			
	Hematocrit	37.5	39	40.5	39	37.5
	BUN (mg/ml)	32	29	31	30	34
	Weight	450				

Injection of 4×10^6 pfu-E (7.4×10^3 pfu/kg) of hd(ratEPO) 9

25 weeks after surgery caused only a minor haematocrit

increase, in agreement with the previous observation the a dose of 1×10^4 pfu-E/gram of body weight was necessary to induce a significant haematocrit increase. It was determined as described above that no anti Adeno neutralizing Abs were
5 detected after the first injection. A second injection of 4×10^7 pfu-E (7.4×10^4 pfu/kg) was performed 5 weeks after the first. Roughly 5 weeks after the second injection haematocrit increased of 13 points.

10 Thus, hd(ratEPO) injection can correct anemia induced by partial nephrectomy. The biological effect persisted for at least 10 week from the first injection. Furthermore, the virus can be readministered i.v. also in rats, consistently with what has been shown in mice.

15

EXAMPLE 14

Comparison of hd(pSTK-ITR-mEPO)Ad with a first generation virus delivered by intra-muscle injection

20 A number of studies have been published by other laboratories using first generation Adeno vectors carrying the EPO gene, indicating the limitations of such vectors in providing appropriate gene dosage.

25 For example, mouse EPO cDNA was delivered using a first generation Adeno vector (AdmEPO) injected in muscle by Svensson et al. (1997).

Figure 9 shows that 10^9 pfu of first generation Adeno vector AdmEPO (data are derived from Figure 1A in Svensson et al., 1997) are necessary to induce in CD-1 mice the same haematocrit increase induced by the injection of 10^6 pfu-E of
5 hd(pSTK-ITR-mEPO)Ad virus.

This indicates that hd(pSTK-ITR-mEPO)Ad virus is roughly 1,000-fold more potent than this particular first generation Adeno vector injected intramuscle in inducing haematocrit
10 increase in immunocompetent CD-1 mice. In agreement with this conclusion, Svensson et al., 1997, states that "there is a treshold dose of virus ($2.5-8 \times 10^7$ pfu/gram of body weight) which is required to obtain long-term Epo expression and polycythemia...". Example 12 above shows that such a
15 threshold for hd(pSTK-ITR-mEPO)Ad virus is 1×10^4 pfu-E/gram of body weight (2,500-8,000-fold less).

EXAMPLE 15

Comparison of hd(pSTK-ITR-mEPO)Ad with a first generation
20 virus delivered by intravenous injection

EPO cDNA was also delivered using a first generation Adeno vector (Ad.RSVEpo) injected intravenously by Descamp et al. (1994).

25

Figure 10 shows that 5×10^9 pfu of Ad.RSVEpo injected intravenously (data are derived from Table 1 in Descamp et

al., 1994) are not even sufficient to induce in DBA/2J mice the same haematocrit increase induced by the injection of 3×10^5 pfu-E (the lowest dose tested) of hd(pSTK-ITR-mEPO)Ad virus.

5

This indicates that hd(pSTK-ITR-mEPO)Ad virus is roughly 10,000-fold more potent than this particular first generation Adeno vector injected intravenously in inducing haematocrit increase in immunocompetent DBA/2J mice.

10

Therefore, the efficacy *in vivo* on a particle basis of the hd(pSTK-ITR-mEPO)Ad virus vector is far superior (1,000- to 10,000-fold) to first generation Adenoviruses carrying mouse EPO reported in the literature.

15

In a further experiment, the efficiency of *in vivo* gene transfer of HD-mEPO and of Ad-mEPO was compared by injecting the two viruses i.v. in the tail vein of BALB/c mice.

20 In mice injected with HVAd-mEPO, the haematocrit initially increased and subsequently decreased in all injection groups (Figure 3A). For the two lower doses (3×10^6 and 1×10^7 pfu), haematocrit reached control values at day 35 and at day 64 p.i., respectively (Figure 3A) whereas the
25 haematocrit remained elevated in mice injected with HD-mEPO (Figure 3B). Interestingly, 64 days p.i. mice infused with 3×10^7 pfu of HVAd-mEPO had an haematocrit of $62 \pm 6.4\%$, which

is not significantly different from the haematocrit of mice injected with 3×10^5 i.u. of HD(pSTK-ITR-mEPO)Ad ($57 \pm 5.6\%$ in this experiment). Therefore, the HD vector is roughly 100-fold more effective than a first-generation vector in
5 inducing haematocrit increase in adult immunocompetent BALB/c mice.

CLAIMS

1. Use of an adenoviral vector in which the entire
Adenoviral genome coding sequences have been removed and
5 substituted with exogenous stuffer DNA and including nucleic
acid encoding erythropoietin operably linked to regulatory
sequences for production of erythropoietin by expression
from the nucleic acid, in the manufacture of a medicament
for treatment of a mammal to provide a level of at least 5
10 mU erythropoietin/ml serum in the mammal and/or an increase
in haematocrit of at least 5%.
2. Use according to claim 1 wherein said level is at least
150 mU/ml.
- 15 3. Use according to claim 2 wherein said level is at least
1 U/ml.
4. Use according to claim 1 wherein said level is from 5
20 mU/ml to 2 U/ml.
5. Use according to claim 1 wherein said increase in
haematocrit is from 5% to 100%.
- 25 6. Use according to any one of claims 1 to 5 wherein said
level or increase is stable for at least about a month.

7. Use according to claim 6 wherein said level or increase is stable for at least 85 days.

8. Use according to claim 6 wherein said level or increase
5 is stable from one to 18 months.

9. Use according to claim 1 wherein the medicament is for administration of a dosage of from about 1×10^3 to 1×10^6 adenoviral particles/g body weight of the mammal.

10

10. Use according to claim 9 wherein the dosage is about 1×10^4 /g body weight.

11. Use according to any one of the preceding claims
15 wherein the medicament is for repeated administration to the mammal.

12. An adenoviral vector in which the entire Adenoviral genome coding sequences have been removed and substituted
20 with exogenous stuffer DNA and including nucleic acid encoding erythropoietin operably linked to regulatory sequences for production of erythropoietin by expression from the nucleic acid, for use in a method of treatment to provide a level of at least 5 mU erythropoietin/ml serum in
25 a mammalian body and/or an increase in haematocrit of at least 5%.

13. An adenoviral vector according to claim 12 wherein said level is at least 150 mU/ml.
14. An adenoviral vector according to claim 13 wherein said
5 level is at least 1 U/ml.
15. An adenoviral vector according to claim 12 wherein said level is from 5 mU/ml to 2 U/ml.
- 10 16. An adenoviral vector according to claim 12 wherein said increase in haematocrit is from 5% to 100%.
17. An adenoviral vector according to any one of claims 12 to 16 wherein said level or increase is stable for at least
15 about a month.
18. An adenoviral vector according to claim 17 wherein said level or increase is stable for at least 85 days.
- 20 19. An adenoviral vector according to claim 17 wherein said level or increase is stable from one to 18 months.
20. An adenoviral vector according to claim 12, for administration in a dosage of from about 1×10^3 to 1×10^6
25 adenoviral particles/g body weight of the mammal.
21. An adenoviral vector according to claim 20 wherein the

dosage is about 1×10^4 /g body weight.

22. An adenoviral vector according to any one of claims 12 to 21, for repeated administration to the mammal.

5

23. A method of delivering erythropoietin to a mammal, the method including administering to the mammal an adenoviral vector in which the entire Adenoviral genome coding sequences have been removed and substituted with exogenous
10 stuffer DNA and including nucleic acid encoding erythropoietin operably linked to regulatory sequences for production of erythropoietin in the mammal by expression from the nucleic acid, whereby on such expression a level of at least 5 mU erythropoietin is provided per ml serum in the
15 mammal and/or an increase in haematocrit of at least 5% is provided in the mammal.

24. A method according to claim 23 wherein said level is at least 150 mU/ml.

20

25. A method according to claim 24 wherein said level is at least 1 U/ml.

26. A method according to claim 23 wherein said level is
25 from 5 mU/ml to 2 U/ml.

27. A method according to claim 23 wherein said increase in

haematocrit is from 5% to 100%.

28. A method according to any one of claims 23 to 27
wherein said level or increase is stable for at least about
5 a month.

29. A method according to claim 28 wherein said level or
increase is stable for at least 85 days.


10 30. A method according to claim 8 wherein said level or
increase is stable from one to 18 months.

31. A method according to claim 23 wherein a dosage is
administered to the mammal of from about 1×10^3 to 1×10^6
15 adenoviral particles/g body weight of the mammal.

32. A method according to claim 31 wherein the dosage is
about 1×10^4 /g body weight.


20 33. A method according to any one of claims 23 to 32,
wherein a said adenoviral vector is repeatedly administered
to the mammal.

Figure 1




2/10

Figure 2



3/10

Figure 3



4/10

Figure 4






Figure 5

5/10





6/10

Figure 6





7/10

Figure 7




8/10

Figure 8




9/10

Figure 9



10/10

Figure 10



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/05661

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/64 C12N15/86 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	M.A. MORSY ET AL.: "An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene" PNAS, vol. 95, 1998, pages 7866-7871, XP002124027 the whole document	1-33
Y	S. KOCHANNEK ET AL.: "A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase" PNAS, vol. 93, 1996, pages 5731-5736, XP000652052 the whole document	1-33

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26 November 1999

Date of mailing of the international search report

15/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marie, A

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/05661

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 32481 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 12 September 1997 (1997-09-12) the whole document -----	1-33
Y	WO 96 13598 A (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA) 9 May 1996 (1996-05-09) the whole document -----	1-33
Y	WO 95 29993 A (THE UNIVERSITY OF MICHIGAN) 9 November 1995 (1995-11-09) the whole document -----	1-33
Y	E.C. SVENSSON ET AL.: "Long-term EPO expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector" HUMAN GENE THERAPY, vol. 8, 1997, pages 1797-1806, XP002124028 the whole document -----	1-33
Y	V. DESCAMPS ET AL.: "EPO gene transfer and expression in adult normal mice: use of an adenovirus vector" HUMAN GENE THERAPY, vol. 5, 1994, pages 979-985, XP002124029 the whole document -----	1-33
Y	S.K. TRIPATHY ET AL.: "Immune responses to transgene encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors" NATURE MEDICINE, vol. 2, no. 5, 1996, pages 545-550, XP002054118 the whole document -----	1-33

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/05661

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9732481 A	12-09-1997	AU 2319497 A	22-09-1997
WO 9613598 A	09-05-1996	US 5856152 A	05-01-1999
		AU 695811 B	20-08-1998
		AU 4405596 A	23-05-1996
		CA 2203808 A	09-05-1996
		EP 0797678 A	01-10-1997
		JP 10507928 T	04-08-1998
		US 5871982 A	16-02-1999
WO 9529993 A	09-11-1995	CA 2189067 A	09-11-1995
		EP 0763103 A	19-03-1997
		JP 10507061 T	14-07-1998